Abstract
We present data on presentation, treatment, and follow-up of 65 pediatric patients with primary hypertension treated over the past 12 years, including initial anthropometric data, pharmacologic treatment, time to control for both systolic and diastolic blood pressure (SBP/DBP), and maintenance of control over time. Data was normalized to standard deviation scores (SDS) for mathematical analysis, and antihypertensive medication dosages were converted to dosage equivalents for a single member of each antihypertensive class. We used multiple regression analysis and Kaplan-Meier survival curves to determine the time to control, medication, and dose effectiveness. Patients were seen for an average of seven visits over 25 months. Initial BPs averaged 134/71 mmHg (2.1/0.6 SDS). Patients were taller, heavier, and had higher body mass index than average for age and sex. By the fourth visit, SBP was <90th percentile in 79%. Ninety percent could be controlled, although 32 lost control at some point (at least 16 due to noncompliance). At the last visit, 46 were controlled, and 5/8 patients off medication remained normotensive. Only angiotensin-converting enzyme inhibitors and β-blockers demonstrated significant association with BP control. This is the first study to document the time to control of BP, and it can serve as an initial standard for quality assessment.
Similar content being viewed by others
References
Chiolero A, Cachat F, Burnier M, Paccaud F, Bovet P (2007) Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight. J Hypertens 25:2209–2217
Din-Dzietham R, Liu Y, Bielo M-V, Shamsa F (2007) High blood pressure trends in children and adolescents in National surveys, 1963 to 2002. Circulation 116:1488–1496
Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ (2004) Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 113:475–482
Bartosh S, Aronson A (1999) Childhood hypertension: an update on etiology, diagnosis, and treatment. Pediatr Clin North Am 46:235–252
Hansen ML, Gunn PW, Kaelber DC (2007) Underdiagnosis of hypertension in children and adolescents. JAMA 298:874–879
Robinson R, Batisky D, Hayes J, Nahata M, Mahan J (2004) Body mass index in primary and secondary pediatric hypertension. Pediatr Nephrol 19:1379–1384
Flynn J, Falkner B (2008) Children and adolescents with obesity-associated high blood pressure. J Am Soc Hypertens 2:267–274
Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos N (2005) Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension 45:602–607
Freedman D, Dietz W, Srinivasan S, Berensen G (1999) The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa heart study. Pediatrics 103:1175–1182
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004). The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:1−22
Zemel MB (1997) Dietary pattern and hypertension: the DASH study. Dietary approaches to stop hypertension. Nutr Rev 55:303–305
Wells T, Stowe C (2001) An approach to the use of antihypertensive drugs in children and adolescents. Curr Ther Res Clin E 62:329–350
Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL (2000) CDC Growth Charts: United States. Adv Data 1−27
Bailey KR, Grossardt BR, Graves JW (2008) Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension 51:841–847
Physician’s Desk Reference (2008) 62 ed. 2008, Montvale Thompson Healthcare Inc
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, The National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252
Sieber US, von Vigier RO, Sforzini C, Fossali E, Edefonti A, Bianchetti MG (2003) How good is blood pressure control among treated hypertensive children and adolescents? J Hypertens 21:633–637
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497
Michaud P, Suris J, Viner R (2004) The adolescent with a chronic condition. Part II: healthcare provision. Arch Dis Child 89:943–949
Winnick S, Lucas D, Hartman A, Toll D (2005) How do you improve compliance? Pediatrics 115:718–724
Rianthavorn P, Ettenger R (2005) Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint. Pediatr Transplant 9:398–407
Woroniecki R, Flynn J (2005) How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologist. Pediatr Nephrol 20:791–797
Flynn J, Daniels S (2006) Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 149:746–754
Paradis G, Lambert M, O'Loughlin J, Lavallee C, Aubin J, Delvin E, Levy E, Hanley JA (2004) Blood pressure and adiposity in children and adolescents. Circulation 110:1832–1838
Israeli E, Schochat T, Korzets Z, Tekes-Manova D, Bernheim J, Golan E (2006) Prehypertension and obesity in adolescents: a population study. Am J Hypertens 19:708–712
Koulouridis E, Georgalidis K, Kostimpa I, Kalantzi M, Ntouto P, Koulouridis I, Mandyla M, Krokida A, Boulgari N (2008) Factors influencing blood pressure control in children and adolescents. Int Urol Nephrol 40:741–748
Podoll A, Grenier M, Croix B, Feig DI (2007) Inaccuracy in pediatric outpatient blood pressure measurement. Pediatrics 119:e538–e543
Swartz SJ, Srivaths PR, Croix B, Feig DI (2008) Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics 122:1177–1181
Sorof JM, Portman RJ (2000) Ambulatory blood pressure monitoring in the pediatric patient. J Pediatr 136:578–586
Gavrilovici C, Goldsmith DJ, Reid C, Gubeth-Tatomir P, Covic A (2004) What is the role of ambulatory BP monitoring in pediatric nephrology? J Nephrol 17:642–652
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Calculation of antihypertensive dosage equivalents
Medication class | Base medication | Medication administered | × Conversion factor |
---|---|---|---|
Angiotensin-converting enzyme inhibitors (ACEI) | Enalapril equivalents | Enalapril | 1 |
Lisinopril | 1 | ||
Fosinopril or quinapril or benazepril | 0.5 | ||
Ramipril | 2 | ||
β-blockers | Propranolol | Propranolol | 1 |
Atenolol | 6.4 | ||
Metoprolol | 1.42 | ||
Calcium-channel inhibitors | Amlodipine | Amlodipine | 1 |
Nifedipine | 0.055 | ||
Thiazide diuretics | Hydrochlorothiazide | Hydrochlorothiazide | 1 |
Chlorothiazide | 0.1 | ||
Angiotensin receptor blockers | Valsartan | Valsartan | 1 |
Losartan | 3.2 | ||
Olmesartan | 8 |
Rights and permissions
About this article
Cite this article
DiPietro, A., Kees-Folts, D., DesHarnais, S. et al. Primary hypertension at a single center: treatment, time to control, and extended follow-up. Pediatr Nephrol 24, 2421–2428 (2009). https://doi.org/10.1007/s00467-009-1297-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1297-4